Vitiligo
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Vitiligo ti awọn ika ọwọ jẹ nira sii lati tọju ju awọn agbegbe miiran lọ. Yato si lati jẹ aibikita ohun ikunra, vitiligo jẹ deede ati pe ko ni ran. Ni Ẹkọ-ara, itọju ti o munadoko julọ jẹ phototherapy tabi itọju laser (excimer) ni igba 2-3 ni ọsẹ kan fun o kere ju ọdun kan. Ti o ko ba le lọ si ile-iwosan nigbagbogbo fun awọn idi inawo tabi nitori o n ṣiṣẹ lọwọ, o le gbiyanju ẹrọ itọju fọto ti o fọwọsi fun lilo ile.
Eyelid vitiligo
Vitiligo ni ọwọ
References
Vitiligo jẹ ibajẹ awọ ara ti o wọpọ ti o fa awọn abulẹ ti awọ funfun nitori isonu ti melanocytes. Iwadi aipẹ fihan pe o jẹ arun autoimmune. Lakoko ti o ti n rii nigbagbogbo bi ọrọ ikunra, o le ni ipa jinna ilera ọpọlọ ati igbesi aye ojoojumọ. Ni ọdun 2011, awọn amoye pin iru kan ti a pe ni segmental vitiligo lọtọ si awọn miiran.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Awọn alaisan vitiligo ti nṣiṣe lọwọ ni ọpọlọpọ awọn aṣayan itọju ailera, gẹgẹbi awọn glucocorticoids eto, phototherapy, ati awọn ajẹsara eto eto. Awọn alaisan vitiligo iduroṣinṣin le rii iderun lati awọn corticosteroids ti agbegbe, awọn inhibitors calcineurin ti agbegbe, phototherapy, ati awọn ilana gbigbe. Awọn ilọsiwaju aipẹ ni oye awọn ilana abẹlẹ ti vitiligo ti yori si idagbasoke awọn itọju ti a fojusi. Lọwọlọwọ, awọn inhibitors JAK jẹ ti o ni ileri julọ, ti o funni ni ifarada ti o dara ati awọn abajade iṣẹ, laibikita eewu ti ṣiṣiṣẹ awọn akoran latent ati awọn ipa ẹgbẹ eto eto ti o wọpọ pẹlu awọn aṣoju ajẹsara miiran. Iwadi ti nlọ lọwọ ni ero lati ṣe idanimọ awọn cytokines bọtini ti o ni ipa ninu idagbasoke vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Idilọwọ awọn cytokines wọnyi ti han ileri ni awọn awoṣe ẹranko ati diẹ ninu awọn alaisan. Ni afikun, awọn iwadii si miRNA-based therapeutics ati adoptive Treg cell therapy ti nlọ lọwọ.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ko si arowoto ti a mọ fun vitiligo. Fun awọn ti o ni awọ ina, iboju oorun ati atike ni gbogbo eyiti a ṣe iṣeduro ni igbagbogbo. Awọn aṣayan itọju miiran le pẹlu awọn ipara sitẹriọdu tabi phototherapy.
○ Itọju
#Phototherapy
#Excimer laser
#Tacrolimus ointment